Health News Releases

  • Today February 18
October 19, 2015 13:55
New CPR Guidelines Recommend Using Social Media and Mobile Technology to Speed Bystander CPR in Sudden Cardiac Arrests
For the first time, CPR guidelines (https://goo.gl/6vMmWF) issued by the American Heart Association (AHA) recommend that communities consider using social media and mobile app technology to alert CPR
October 16, 2015 17:50
Quintiles Named 2015 Frost & Sullivan Asia Pacific CRO Company of the Year
Citing Quintiles' (www.quintiles.com) innovation, customer service and growth, Frost & Sullivan has named Quintiles as its Asia Pacific Contract Research Organization Company of the Year. “Quintile
October 16, 2015 11:40
GN ReSound and Cochlear Limited Establish Smart Hearing Alliance to Develop and Commercialise Bimodal Solutions
GN ReSound, the leader in Smart Hearing™ aids, and Cochlear Limited (ASX:COH), the global leader in implantable hearing solutions, today announced a strategic alliance to develop the world’s smartest
October 15, 2015 13:45
Quintiles Recognized as Phase I Services Leader for Third Consecutive Year
For the third year in a row, Quintiles has been named the industry leader in Phase I services according to respondents in Industry Standard Research’s (ISR) 2015 CRO Quality Benchmarking - Phase I Ser
October 14, 2015 13:50
Cell Signaling Technology Expands Portfolio with GMP Capabilities
Cell Signaling Technology, Inc. (CST), a worldwide provider of high quality antibodies, announced today that their best-in-class recombinant rabbit monoclonal antibodies, developed with their propriet
October 14, 2015 13:45
CardioKinetix Announces South Korean Approval for the Parachute System for Heart Failure
CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that it has received regulatory approval for the Parachute® System in South Korea
October 14, 2015 13:30
Joe Kiani to Deliver Keynote Address at Brazil’s Inaugural Foundation for Patient Safety Symposium
The Society of Anesthesiology of the State of São Paulo (SAESP) announced today that Joe Kiani, Founder of the Patient Safety Movement Foundation, will deliver the keynote address at the first annual
October 13, 2015 13:55
Quintiles Wins Society for Clinical Research Sites’ 2015 Eagle Award
Quintiles today announced that it has been awarded the Society for Clinical Research Sites’ (SCRS) 2015 Clinical Research Organization (CRO) Eagle Award. Presented during the annual SCRS Site Solution
October 13, 2015 09:50
One Year Data from Phase III Study Evaluating Oral OTEZLA® (apremilast) or Injectable etanercept versus Placebo in Patients with Moderate to Severe Plaque Psoriasis Presented at EADV
Celgene International Sàrl, a wholly owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced that results from its ongoing phase III LIBERATE™ trial evaluating Otezla® (apremilast), th
October 12, 2015 14:40
New Cancer Research Funding Effort Announced by Feld Entertainment and Primary Children’s Hospital
The Feld Family, owners of Feld Entertainment, Inc., the parent company of Ringling Bros. and Barnum & Bailey® and the Ringling Bros. Center for Elephant Conservation®, announced yesterday a new fundi
October 12, 2015 13:30
Feld Entertainment and Primary Children’s Hospital Announce New Cancer Research Funding Effort
The Feld Family, owners of Feld Entertainment, Inc., the parent company of Ringling Bros. and Barnum & Bailey® and the Ringling Bros. Center for Elephant Conservation®, announced today a new funding e
October 12, 2015 11:20
Masimo PVI® Evaluated in 18-Study Meta-Analysis for Ability to Help Clinicians Assess Fluid Responsiveness
Masimo (www.masimo.com) (NASDAQ: MASI) announced today that an 18-study meta-analysis of 665 subjects reported that Masimo’s Pleth Variability Index (PVI®), available with Masimo’s SET® and rainbow® S
October 12, 2015 09:25
Celgene Announces New Data for OTEZLA® (Apremilast) Will Be Presented at European Academy of Dermatology and Venereology Congress
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ:CELG), today announced that the latest research on Otezla® (apremilast), the Company's oral, selective inhibitor of
October 09, 2015 12:45
Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study
New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066*, over ustekinumab. After nine months, 69 percen
October 09, 2015 12:20
Octapharma AG Invests €80 Million to Acquire an Exclusive Worldwide License to Certain IP of Glycotope’s Recombinant Technology and to Become a Minority Shareholder of Glycotope GmbH Berlin
Octapharma AG invests €80 million to acquire an exclusive worldwide license to certain IP of Glycotope’s recombinant technology and to become a minority shareholder of Glycotope GmbH Berlin. This S
October 08, 2015 17:45
Merck and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma
Merck and Pfizer today announced that the US Food and Drug Administration (FDA) has granted avelumab*, an investigational fully human anti-PD-L1 IgG1 monoclonal antibody, Fast Track designation for th
October 08, 2015 17:35
Delayed IPF Diagnosis Negatively Impacts Patients by Delaying Treatment According to Global Survey of Pulmonologists[1]
A new survey of over 400 pulmonologists from 10 countries found that 88% of pulmonologists believe a delay in the diagnosis of idiopathic pulmonary fibrosis (IPF) negatively impacts patients. 79% stat
October 08, 2015 15:00
ReSound® Brings Industry-Leading Hearing Aid Portfolio to EUHA 2015
ReSound is pleased to return to EUHA’s 60th International Congress of Hearing Aid Acousticians next week in Nuremberg, Germany, to showcase the industry’s most comprehensive portfolio of hearing solut
October 08, 2015 11:35
Cell Therapy Catapult Launches Cell History File
The Cell Therapy Catapult, the organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the
October 07, 2015 11:50
FDA Approves Optune in Combination with Temozolomide for the Treatment of Newly Diagnosed Glioblastoma
Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune in combination with temozolomide for the treatment of adult patients with newly diagnosed g
October 06, 2015 14:30
SafeCare Magazine Selects Joe Kiani as Person of the Year
SafeCare Magazine announced today that Joe Kiani, Founder of the Patient Safety Movement Foundation and CEO of Masimo, was awarded Person of the Year for 2015. This award recognizes and applauds the o
October 06, 2015 13:35
Replicor Announces Initiation of Recruitment for Its Phase IIb Clinical Trial with REP 2139-Mg or REP 2165-Mg in Combination with Viread® and Pegasys® or Zadaxin® in Patients with HBeAg Negative Chronic Hepatitis B Infection
Replicor announces that the recruitment of patients is underway for its second Phase II trial in Caucasian patients that will assess the safety and antiviral efficacy of REP 2139-Mg or REP 2165-Mg in
October 02, 2015 11:00
HOYA Group PENTAX Medical Announces Expansion into Endoscopic Therapy through Strategic Investment in Creo Medical Ltd.
HOYA Group PENTAX Medical has entered into an agreement to invest in Creo Medical Ltd., a leading electrosurgical energy devices company based in the U.K. The official documents formalizing the agreem
October 02, 2015 03:10
ReSound® Launches New Wireless Hearing Aid, Bringing Industry-Leading Connectivity and Sound Quality to Wearers Where Budget Matters
ReSound today announced the global launch of the ReSound Enya family of hearing aids, making the company’s industry-leading, innovative hearing technologies accessible to even more people living with
September 30, 2015 17:20
New data demonstrate sustained long-term efficacy of OFEV®* on slowing disease progression and safety in patients with IPF
An interim analysis of the INPULSIS®-ON extension trial has confirmed the efficacy and safety of OFEV®* (nintedanib) previously observed in the INPULSIS® trials.[1] The results were presented at the E
25 per page50 per page75 per page100 per page